Apollomics regains compliance with nasdaq's minimum bid price requirement

Foster city, calif., dec. 10, 2024 (globe newswire) -- apollomics inc. (nasdaq: aplm) (the “company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on december 10, 2024, it received a notification (the “notice”) from the nasdaq stock market llc (“nasdaq”) stating that the company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in nasdaq rule 5550(a)(2) (the “bid price requirement”), and nasdaq has determined to continue the listing of the company's class a ordinary shares (“class a ordinary shares”) on the nasdaq capital market under the symbol “aplm.”
APLM Ratings Summary
APLM Quant Ranking